Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Retinal Hyperspectral Imaging in Neurodegenerative Diseases

NCT: NCT07545473 · RECRUITING

NCT IDNCT07545473
StatusRECRUITING
Start Date2021-10-11
Completion2028-12-31

Brief Summary

Hyperspectral retinal imaging is a non-invasive imaging modality in which a series of images of the retina are captured using light of different wavelengths. The resulting "hypercube" of data provides a wealth of information about the retinal structure. Our group has developed evidence supporting a role for this technology in the detection of retinal amyloid beta in Alzheimer's disease. We are undertaking further studies to establish the role of this method in the assessment of people with dementia, or those at risk of Alzheimer's disease. In addition, we wish to test whether the approach may have value in other forms of dementia or neurodegenerative disease such as Parkinson's disease, Lewy-Body dementia or vascular dementia.

Frequently Asked Questions

What is Retinal Hyperspectral Imaging in Neurodegenerative Diseases?

Retinal Hyperspectral Imaging in Neurodegenerative Diseases is a clinical trial registered under NCT07545473. Current status: RECRUITING.

What is the status of NCT07545473?

The current status of NCT07545473 (Retinal Hyperspectral Imaging in Neurodegenerative Diseases) is: RECRUITING.

When did Retinal Hyperspectral Imaging in Neurodegenerative Diseases start?

Retinal Hyperspectral Imaging in Neurodegenerative Diseases started on 2021-10-11.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.